Revising Pooled Cohort Equations Improves CVD Risk Prediction

Share this content:
Revising Pooled Cohort Equations Improves CVD Risk Prediction
Revising Pooled Cohort Equations Improves CVD Risk Prediction

MONDAY, June 4, 2018 (HealthDay News) -- Revising the 2013 pooled cohort equations (PCEs) can improve accuracy of cardiovascular disease (CVD) risk prediction, according to a study published online June 5 in the Annals of Internal Medicine.

In an effort to improve the clinical accuracy of CVD risk prediction, Steve Yadlowsky, from Stanford University in California, and colleagues conducted a population-based study involving 26,689 adults aged 40 to 79 years without prior CVD from six U.S. cohorts.

The researchers found that across risk groups, the 2013 PCEs for atherosclerotic CVD overestimated 10-year risk by an average of 20 percent. Misestimation of risk was especially prominent among black adults; 33 percent of eligible black persons (3.9 million) had extreme risk estimates. Among all race and sex subgroups, accuracy was improved by updating these equations. Based on the updated equations, about 11.8 million U.S. adults previously labeled as high-risk by the 2013 PCEs would be relabeled as lower-risk.

"Updating the 2013 PCEs with data from modern cohorts reduced the number of persons considered to be at high risk. Clinicians and patients should consider the potential benefits and harms of reducing the number of persons recommended aspirin, blood pressure, or statin therapy," the authors write. "Our findings also indicate that risk equations will generally become outdated over time and require routine updating."

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »